FDA/CDC

FDA approves first gene therapy – tisagenlecleucel for ALL

Publish date: August 30, 2017

 

At its meeting in July, the FDA ODAC agreed nearly unanimously that the risk mitigation plan put forward by Novartis, including planned 15-year follow-up and other mitigation measures, would be adequate for detecting serious consequences of CAR T-cell therapy.

sworcester@frontlinemedcom.com

This article was updated August 30, 2017.

Pages

Recommended Reading

All FDA panel members go thumbs up for CTL019 in relapsed/refractory childhood ALL
MDedge Hematology and Oncology
Inotuzumab ozogamicin approved for relapsed/refractory ALL
MDedge Hematology and Oncology
Inotuzumab ozogamicin tied to sinusoidal obstruction syndrome in ALL
MDedge Hematology and Oncology
‘Breakthrough’ leukemia drug also portends ‘quantum leap’ in cost
MDedge Hematology and Oncology
Triplet eradicates B-ALL, prolongs survival in mice
MDedge Hematology and Oncology
FDA approves inotuzumab ozogamicin for rel/ref ALL
MDedge Hematology and Oncology
VSTs can treat 5 different viral infections after HSCT
MDedge Hematology and Oncology
ODAC recommends approval of CTL019 in rel/ref ALL
MDedge Hematology and Oncology
Blinatumomab granted full approval to treat rel/ref BCP-ALL
MDedge Hematology and Oncology
Mapping the genomic landscape of T-ALL
MDedge Hematology and Oncology

Related Articles